Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan and Retlirafusp Alfa With or Without CAPOX in Resectable Gastric/GEJ Adenocarcinoma
NCT07802288Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, retlirafusp alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanretlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07802288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802288.